News
03-19-2013, 02:22 AM
Further research also reveals quicker administration of Herceptin could save NHS £15m compared to current practice1 Results from the PrefHer (Patient Preference for Subcutaneous (SC) versus Intravenous (IV) Herceptin) trial show that 92% of early HER2-positive breast cancer patients favoured quicker SC administration of Herceptin compared to the standard IV infusion.1 Presented at the St...
More... (http://www.medicalnewstoday.com/releases/257799.php)
More... (http://www.medicalnewstoday.com/releases/257799.php)